Drug prices to skyrocket with new health insurance company policy, according to Coalition of State Rheumatology Organizations

Coalition of State Rheumatology Organizations

29 January 2020 - Coalition of State Rheumatology Organizations physicians are voicing concern for patients who will fall victim of a dangerous new prescription policy. 

New requirements from BlueCross BlueShield (BCBS) of Tennessee, which may be a bellwether for other insurers, are reversing the trend providers have achieved in keeping prices down for physician administered medications.

Normally provider administered drugs are obtained via a "buy and bill" system where a provider purchases medication and bills the insurance company under a patient's medical benefit. The new BCBS policy moves the acquisition of these administered medication away from the physician to the patient's pharmacy benefit, handled by pharmacy benefit managers.

Read Coalition of State Rheumatology Organizations press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Pricing , Affordability , Costs